Advice
following a full submission:
capecitabine (Xeloda®) is accepted for use within NHS Scotland.
Indication under review: The adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer in combination with oxaliplatin.
At 55 months, disease free survival was significantly increased for capecitabine plus oxaliplatin-treated patients compared with a recognised regimen containing a fluoropyramidine in the adjuvant treatment of patients with completely resected stage III (Dukes' C) colon cancer.
Download detailed advice132KB (PDF)
Medicine details
- Medicine name:
- capecitabine (Xeloda)
- SMC ID:
- 716/11
- Indication:
- In combination with oxaliplatin for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 August 2011